IL10 and neoplasm: IL-10 blockade—achieved using soluble IL-10 receptors (145), peptide-based IL-10 receptor antagonists (146), or oligonucleotide-based inhibitors (147)—may further potentiate antitumor immunity in OCCC by augmenting T-cell responses and reprogramming tumor-associated macrophages (TAMs).